280 related articles for article (PubMed ID: 24625516)
1. Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.
Ferreira JH; Silva Ldos S; Longo-Maugéri IM; Katz S; Barbiéri CL
PLoS Negl Trop Dis; 2014 Mar; 8(3):e2729. PubMed ID: 24625516
[TBL] [Abstract][Full Text] [Related]
2. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi as an antigen for delayed-type hypersensitivity assays and serodiagnosis of canine visceral leishmaniasis.
Pinheiro PH; Pinheiro AN; Ferreira JH; Costa FA; Katz S; Barbiéri CL
Vet Parasitol; 2009 May; 162(1-2):32-9. PubMed ID: 19269098
[TBL] [Abstract][Full Text] [Related]
3. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
[TBL] [Abstract][Full Text] [Related]
4. Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule.
da Silva DAM; Santana FR; Katz S; Garcia DM; Teixeira D; Longo-Maugéri IM; Barbiéri CL
Front Immunol; 2020; 11():345. PubMed ID: 32194563
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
6. A new immunochemotherapy schedule for visceral leishmaniasis in a hamster model.
de Santana FR; da Silva DAM; Katz S; Orikaza CM; Oliveira KC; Barbiéri CL
Parasitol Res; 2022 Oct; 121(10):2849-2860. PubMed ID: 35997843
[TBL] [Abstract][Full Text] [Related]
7. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis.
de Souza Dias S; da Costa Pinheiro PH; Katz S; dos Santos MR; Barbiéri CL
Am J Trop Med Hyg; 2005 Feb; 72(2):126-32. PubMed ID: 15741546
[TBL] [Abstract][Full Text] [Related]
8. [Interpretation of laboratory data during cryptic leishmaniasis in dog].
Gravino AE
Parassitologia; 2004 Jun; 46(1-2):227-9. PubMed ID: 15305723
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Cysteine Proteinase B from Leishmania braziliensis and Its Domains: Promising Antigens for Serodiagnosis of Cutaneous and Visceral Leishmaniasis in Dogs.
Bivona AE; Czentner L; Sanchez Alberti A; Cerny N; Cardoso Landaburu AC; Nevot C; Estévez O; Marco JD; Basombrio MA; Malchiodi EL; Cazorla SI
J Clin Microbiol; 2019 Nov; 57(11):. PubMed ID: 31434727
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of three recombinant Leishmania infantum antigens in human and canine visceral leishmaniasis diagnosis.
Fonseca AM; Faria AR; Rodrigues FT; Nagem RA; Magalhães RD; Cunha JL; Bartholomeu DC; de Andrade HM
Acta Trop; 2014 Sep; 137():25-30. PubMed ID: 24801885
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis.
Shahbazi M; Zahedifard F; Taheri T; Taslimi Y; Jamshidi S; Shirian S; Mahdavi N; Hassankhani M; Daneshbod Y; Zarkesh-Esfahani SH; Papadopoulou B; Rafati S
PLoS One; 2015; 10(7):e0132794. PubMed ID: 26197085
[TBL] [Abstract][Full Text] [Related]
12. An Overview of Immunotherapeutic Approaches Against Canine Visceral Leishmaniasis: What Has Been Tested on Dogs and a New Perspective on Improving Treatment Efficacy.
Gonçalves AAM; Leite JC; Resende LA; Mariano RMDS; Silveira P; Melo-Júnior OAO; Ribeiro HS; de Oliveira DS; Soares DF; Santos TAP; Marques AF; Galdino AS; Martins-Filho OA; Dutra WO; da Silveira-Lemos D; Giunchetti RC
Front Cell Infect Microbiol; 2019; 9():427. PubMed ID: 31921703
[TBL] [Abstract][Full Text] [Related]
13. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
[TBL] [Abstract][Full Text] [Related]
14. Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi.
Reis AB; Teixeira-Carvalho A; Vale AM; Marques MJ; Giunchetti RC; Mayrink W; Guerra LL; Andrade RA; Corrêa-Oliveira R; Martins-Filho OA
Vet Immunol Immunopathol; 2006 Aug; 112(3-4):102-16. PubMed ID: 16621021
[TBL] [Abstract][Full Text] [Related]
15. Performance of a real time PCR for leishmaniasis diagnosis using a L. (L.) infantum hypothetical protein as target in canine samples.
Colombo FA; Pereira-Chioccola VL; Meira Cda S; Motoie G; Gava R; Hiramoto RM; de Almeida ME; da Silva AJ; Cutolo AA; Menz I
Exp Parasitol; 2015 Oct; 157():156-62. PubMed ID: 26297683
[TBL] [Abstract][Full Text] [Related]
16. Further evidence associating IgG1, but not IgG2, with susceptibility to canine visceral leishmaniasis caused by Leishmania (L.) infantum chagasi-infection.
Lima LVDR; Carneiro LA; Campos MB; Vasconcelos Dos Santos T; Ramos PK; Laurenti MD; Teixeira CEC; Silveira FT
Parasite; 2017; 24():37. PubMed ID: 29027520
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled, double-blinded field trial to assess Leishmania vaccine effectiveness as immunotherapy for canine leishmaniosis.
Toepp A; Larson M; Wilson G; Grinnage-Pulley T; Bennett C; Leal-Lima A; Anderson B; Parrish M; Anderson M; Fowler H; Hinman J; Kontowicz E; Jefferies J; Beeman M; Buch J; Saucier J; Tyrrell P; Gharpure R; Cotter C; Petersen C
Vaccine; 2018 Oct; 36(43):6433-6441. PubMed ID: 30219369
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Leishmania infantum pyridoxal kinase protein for the diagnosis of human and canine visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Ludolf F; Steiner BT; Reis TAR; Santos TTO; Costa LE; Martins VT; Galvani NC; Chaves AT; Oliveira JS; Chávez-Fumagalli MA; de Magalhães-Soares DF; Duarte MC; Menezes-Souza D; Silveira JAG; Moreira RLF; Machado-de-Ávila RA; Tupinambás U; Gonçalves DU; Coelho EAF
Immunol Lett; 2020 Apr; 220():11-20. PubMed ID: 31981576
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Leishmania (Leishmania) infantum Ecto-Nucleoside Triphosphate Diphosphohydrolase NTPDase-2 as a new antigen in canine visceral leishmaniasis diagnosis.
de Souza RF; Dos Santos YL; de Souza Vasconcellos R; Borges-Pereira L; Caldas IS; de Almeida MR; Bahia MT; Fietto JL
Acta Trop; 2013 Jan; 125(1):60-6. PubMed ID: 23022017
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
